FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

PAPPAJOHN JOHN 		2. Issuer Name and Ticker or Trading Symbol

CANCER GENETICS, INC [ CGIX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

201 ROUTE 17 NORTH, 2ND FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/25/2016
(Street)

RUTHERFORD, NJ 07070
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share   (1) 5/25/2016     P    317820   A   (2) 2099609   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to buy)   (1) $2.25   5/25/2016     P      158910       11/25/2016   11/25/2021   Common Stock, par value $0.0001 per share   158910.0     (2) 158910   D    

Explanation of Responses:
( 1)  The reported securities were purchased in a registered direct offering and a concurrent private placement, both of which closed on May 25, 2016.
( 2)  The reported securities consist of one share of common stock, par value $0.0001 per share (the "Common Stock") and a warrant to purchase one-half of a share of Common Stock. The purchase price for the reported securities was $2.2025 per share and warrant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
PAPPAJOHN JOHN
201 ROUTE 17 NORTH
2ND FLOOR
RUTHERFORD, NJ 07070 		X X


Signatures
/s/ John Pappajohn by Edward J Sitar as Attorney-in-fact 5/25/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Cancer Genetics Charts.
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Cancer Genetics Charts.